[Experimental and clinical studies on tobramycin by intravenous drip infusion in the field of urology (author's transl)]. 1981

S Okayama, and T Tsukamoto, and A Nishio, and S Sakai, and Y Kumamoto

We carried out experimental and clinical studies on tobramycin (TOB), and the following results obtained. 1. Antibacterial activity Minimum inhibitory concentration (MIC) of TOB against clinically isolated 20 strains of P. aeruginosa, E. coli, K. pneumoniae, P. mirabilis, S. marcescens and S. faecalis was determined. Except of S. marcescens, the great part of those strains were under than 25 micrograms/ml. 2. Clinical effect TOB was treated 11 patients with chronic complicated urinary tract infection in the dose of 40-60 mg twice a day for 5 days by intravenous drip infusion. Clinical effect was excellent in 2 patients, good in 4 and poor in 5, efficacy rate was 55%. In bacteriological effects, eradication rate of causative 12 strains was 67%. Side effect was not observed for all cases.

UI MeSH Term Description Entries
D007263 Infusions, Parenteral The administration of liquid medication, nutrient, or other fluid through some other route than the alimentary canal, usually over minutes or hours, either by gravity flow or often by infusion pumping. Intra-Abdominal Infusions,Intraperitoneal Infusions,Parenteral Infusions,Peritoneal Infusions,Infusion, Intra-Abdominal,Infusion, Intraperitoneal,Infusion, Parenteral,Infusion, Peritoneal,Infusions, Intra-Abdominal,Infusions, Intraperitoneal,Infusions, Peritoneal,Intra Abdominal Infusions,Intra-Abdominal Infusion,Intraperitoneal Infusion,Parenteral Infusion,Peritoneal Infusion
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial

Related Publications

S Okayama, and T Tsukamoto, and A Nishio, and S Sakai, and Y Kumamoto
September 1981, The Japanese journal of antibiotics,
S Okayama, and T Tsukamoto, and A Nishio, and S Sakai, and Y Kumamoto
November 1981, The Japanese journal of antibiotics,
S Okayama, and T Tsukamoto, and A Nishio, and S Sakai, and Y Kumamoto
July 1981, Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases,
S Okayama, and T Tsukamoto, and A Nishio, and S Sakai, and Y Kumamoto
August 1981, The Japanese journal of antibiotics,
S Okayama, and T Tsukamoto, and A Nishio, and S Sakai, and Y Kumamoto
August 1981, The Japanese journal of antibiotics,
S Okayama, and T Tsukamoto, and A Nishio, and S Sakai, and Y Kumamoto
September 1981, The Japanese journal of antibiotics,
S Okayama, and T Tsukamoto, and A Nishio, and S Sakai, and Y Kumamoto
April 1984, The Japanese journal of antibiotics,
S Okayama, and T Tsukamoto, and A Nishio, and S Sakai, and Y Kumamoto
October 1981, The Japanese journal of antibiotics,
S Okayama, and T Tsukamoto, and A Nishio, and S Sakai, and Y Kumamoto
April 1982, The Japanese journal of antibiotics,
S Okayama, and T Tsukamoto, and A Nishio, and S Sakai, and Y Kumamoto
February 1982, The Japanese journal of antibiotics,
Copied contents to your clipboard!